Seattle Genetics announces positive OS, PFS, ORR for tucatinib in HER2+ breast cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Seattle Genetics Inc. announced positive pivotal data from the HER2CLIMB trial evaluating tucatinib in patients with HER2-positive metastatic breast cancer.

“Tucatinib demonstrated a statistically significant and clinically meaningful benefit in overall survival, progression-free survival and objective response rate compared to the control arm,” said Roger Dansey, chief medical officer at Seattle Genetics. “We plan to submit a New Drug Application to FDA and a Marketing Authorization Application to the European Medicines Agency by the first quarter of 2020, with the goal of bringing a much-needed new medicine to patients.”

The results were presented at the 2019 San Antonio Breast Cancer Symposium and published in the New England Journal of Medicine. The data presented include the primary endpoint of PFS as assessed by blinded independent central review in the first 480 patients enrolled in the trial. HER2CLIMB enrolled a total of 612 patients to support the analyses of key secondary endpoints, including OS as well as PFS in patients with brain metastases at baseline.

The HER2CLIMB trial compared tucatinib in combination with trastuzumab and capecitabine to trastuzumab and capecitabine alone in patients with unresectable locally advanced or metastatic HER2-positive breast cancer. Patients had previously received trastuzumab, pertuzumab and ado-trastuzumab emtansine. Patients had received a median of four prior lines of therapy overall and three lines in the metastatic setting.

Forty-seven percent of the patients enrolled in the trial had brain metastases at the time

of enrollment. HER2CLIMB is the first randomized pivotal trial completed to enroll patients with metastatic HER2-positive breast cancer who have untreated or previously treated and progressing brain metastases.

Tucatinib is an oral, small molecule tyrosine kinase inhibitor that is highly selective for HER2.

“Following progression on trastuzumab, pertuzumab and T-DM1 in the metastatic HER2-positive breast cancer setting, there is no single standard of care regimen and clinical trial participation is often strongly encouraged. There is a significant unmet medical need for these patients, particularly those who develop brain metastases,” said Rashmi Murthy, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center.

“The addition of tucatinib to the commonly used combination of trastuzumab and capecitabine improved overall survival, reducing the risk of death by 34 percent compared to trastuzumab and capecitabine alone. The results from HER2CLIMB demonstrate tucatinib has the potential to become a new treatment option for patients who have been previously treated with multiple anti-HER2 agents, including patients with and without brain metastases.”

Table of Contents

YOU MAY BE INTERESTED IN

The tremendous promise—and potential peril—of the prostate-specific antigen (PSA) screening test have confounded guideline developers for decades. When introduced, PSA was one of the first and the only credible blood biomarkers for cancer screening. That a simple blood test should be used to screen for the most common cancer in men, one that was lethal for 3% of men and 5% of Black men, seemed like a slam dunk. 
With artificial intelligence becoming an increasingly ubiquitous part of the fabric of modern life, Cancer Grand Challenges has committed $10 million to a project aimed at developing AI “co-scientists”—AI agents that could help cancer researchers analyze data, generate hypotheses, and suggest new experiments.
For decades, cancer treatment has largely followed a familiar model: Identify the disease, determine its stage, and select the therapy most likely to benefit patients with similar characteristics. Even as targeted therapies and immunotherapies have transformed oncology, we have generally developed drugs for populations rather than individuals.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login